AU2023217097A1 - Use of roluperidone in preventing relapse in schizophrenia patients - Google Patents
Use of roluperidone in preventing relapse in schizophrenia patients Download PDFInfo
- Publication number
- AU2023217097A1 AU2023217097A1 AU2023217097A AU2023217097A AU2023217097A1 AU 2023217097 A1 AU2023217097 A1 AU 2023217097A1 AU 2023217097 A AU2023217097 A AU 2023217097A AU 2023217097 A AU2023217097 A AU 2023217097A AU 2023217097 A1 AU2023217097 A1 AU 2023217097A1
- Authority
- AU
- Australia
- Prior art keywords
- roluperidone
- patient
- schizophrenia
- schizophrenia patient
- symptoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263309874P | 2022-02-14 | 2022-02-14 | |
| US63/309,874 | 2022-02-14 | ||
| PCT/US2023/062500 WO2023154927A1 (en) | 2022-02-14 | 2023-02-13 | Use of roluperidone in preventing relapse in schizophrenia patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023217097A1 true AU2023217097A1 (en) | 2024-08-29 |
Family
ID=85569991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023217097A Pending AU2023217097A1 (en) | 2022-02-14 | 2023-02-13 | Use of roluperidone in preventing relapse in schizophrenia patients |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230255953A1 (https=) |
| EP (2) | EP4479049B1 (https=) |
| JP (1) | JP2025505261A (https=) |
| KR (1) | KR20240161650A (https=) |
| CN (1) | CN118984705A (https=) |
| AU (1) | AU2023217097A1 (https=) |
| CA (1) | CA3243767A1 (https=) |
| CL (1) | CL2024002418A1 (https=) |
| ES (1) | ES3064313T3 (https=) |
| IL (1) | IL314859A (https=) |
| MX (1) | MX2024009828A (https=) |
| WO (1) | WO2023154927A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL319156A (en) | 2017-06-21 | 2025-04-01 | Minerva Neurosciences Inc | Controlled-release oral dosage forms are resistant to gastric acid. |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7166617B2 (en) | 2000-02-29 | 2007-01-23 | Mitsubishi Pharma Corporation | Cyclic amide derivatives |
| PL3227273T3 (pl) | 2014-12-02 | 2022-05-30 | Minerva Neurosciences, Inc. | Kompozycje zawierające 2-((1-(2-(4-fluorofenylo)-2-oksoetylo)piperydyn-4-ylo)metylo)izoindolin-1-on do leczenia schizofrenii |
| IL319156A (en) | 2017-06-21 | 2025-04-01 | Minerva Neurosciences Inc | Controlled-release oral dosage forms are resistant to gastric acid. |
| WO2020264486A1 (en) * | 2019-06-28 | 2020-12-30 | Teva Czech Industries S.R.O | Solid state forms of roluperidone and salts thereof |
-
2023
- 2023-02-13 EP EP23710619.0A patent/EP4479049B1/en active Active
- 2023-02-13 JP JP2024547680A patent/JP2025505261A/ja active Pending
- 2023-02-13 AU AU2023217097A patent/AU2023217097A1/en active Pending
- 2023-02-13 US US18/168,028 patent/US20230255953A1/en active Pending
- 2023-02-13 WO PCT/US2023/062500 patent/WO2023154927A1/en not_active Ceased
- 2023-02-13 EP EP25223916.5A patent/EP4729122A2/en active Pending
- 2023-02-13 KR KR1020247031088A patent/KR20240161650A/ko active Pending
- 2023-02-13 IL IL314859A patent/IL314859A/en unknown
- 2023-02-13 CA CA3243767A patent/CA3243767A1/en active Pending
- 2023-02-13 CN CN202380033205.7A patent/CN118984705A/zh active Pending
- 2023-02-13 ES ES23710619T patent/ES3064313T3/es active Active
-
2024
- 2024-08-12 CL CL2024002418A patent/CL2024002418A1/es unknown
- 2024-08-12 MX MX2024009828A patent/MX2024009828A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3243767A1 (en) | 2023-08-17 |
| WO2023154927A1 (en) | 2023-08-17 |
| EP4479049B1 (en) | 2025-12-17 |
| US20230255953A1 (en) | 2023-08-17 |
| EP4729122A2 (en) | 2026-04-22 |
| JP2025505261A (ja) | 2025-02-21 |
| IL314859A (en) | 2024-10-01 |
| CL2024002418A1 (es) | 2024-12-13 |
| EP4479049A1 (en) | 2024-12-25 |
| CN118984705A (zh) | 2024-11-19 |
| ES3064313T3 (en) | 2026-04-23 |
| MX2024009828A (es) | 2024-11-08 |
| KR20240161650A (ko) | 2024-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Stahl | Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline | |
| Kramer et al. | Paliperidone extended-release tablets for prevention of symptom recurrence in patients with schizophrenia: a randomized, double-blind, placebo-controlled study | |
| Comer et al. | Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial | |
| TWI776407B (zh) | 激動劑形成之調配物及使用其之方法 | |
| EP3010506B1 (en) | Pridopidine in treating huntington's disease | |
| Miyamoto et al. | Antipsychotic drugs | |
| Mischoulon et al. | Randomized, proof-of-concept trial of low dose naltrexone for patients with breakthrough symptoms of major depressive disorder on antidepressants | |
| US11090297B2 (en) | Pridopidine for treating huntington's disease | |
| US20250352533A1 (en) | Pridopidine for treating huntington's disease | |
| Bobo et al. | Risperidone long-acting injectable (Risperdal Consta®) for maintenance treatment in patients with bipolar disorder | |
| JP2022524008A (ja) | うつ病の治療のためのエスケタミン | |
| Wright et al. | Nefazodone and cyclosporine drug–drug interaction | |
| Hartrick | Tapentadol immediate release for the relief of moderate-to-severe acute pain | |
| EP4479049A1 (en) | Use of roluperidone in preventing relapse in schizophrenia patients | |
| Greenberg et al. | Paliperidone palmitate for schizoaffective disorder: a review of the clinical evidence | |
| Sağlam et al. | Treatment of sleep bruxism with a single daily dose of buspirone in a 7-year-old boy | |
| Varallo-Rodriguez et al. | Bosutinib for the treatment of Philadelphia chromosome-positive leukemias | |
| EP4301367A1 (en) | Use of luvadaxistat for the treatment of cognitive impairment | |
| DeMoss et al. | Central nervous system xanthoma disseminatum: Response to 2CdA in an adolescent | |
| Aggarwal et al. | Milnacipran-associated urinary retention: a case report | |
| Stein et al. | Management of treatment-resistant obsessive-compulsive disorder | |
| López-Muñoz et al. | Combination strategies in treatment-resistant depression | |
| Ally | Development and evaluation of a standardised pathway for clozapine use in treatment resistant schizophrenia in institutionalised patients | |
| Maguire et al. | Reply to Comments by Dr Ingham Regarding Maguire et al (J Clin Psychopharmacol. 2010; 30: 48-56) | |
| CN118510513A (zh) | 治疗与阿尔茨海默氏病相关的激越的方法 |